Singapore markets close in 1 hour 7 minutes
  • Straits Times Index

    3,130.30
    +28.37 (+0.91%)
     
  • Nikkei

    27,927.37
    -102.20 (-0.36%)
     
  • Hang Seng

    23,348.65
    -418.04 (-1.76%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • BTC-USD

    48,275.66
    -1,175.79 (-2.38%)
     
  • CMC Crypto 200

    1,234.60
    -207.16 (-14.37%)
     
  • S&P 500

    4,538.43
    -38.67 (-0.84%)
     
  • Dow

    34,580.08
    -59.72 (-0.17%)
     
  • Nasdaq

    15,085.47
    -295.83 (-1.92%)
     
  • Gold

    1,783.00
    -0.90 (-0.05%)
     
  • Crude Oil

    67.81
    +1.55 (+2.34%)
     
  • 10-Yr Bond

    1.3430
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,485.95
    -15.79 (-1.05%)
     
  • Jakarta Composite Index

    6,570.77
    +32.27 (+0.49%)
     
  • PSE Index

    7,130.74
    +75.55 (+1.07%)
     

Organon Launches New Fertility Journey Website as Part of Ongoing Commitment to Help Address the Needs of Women

  • Oops!
    Something went wrong.
    Please try again later.
·5-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Website aims to provide information on the fertility journey including, but not limited to, preparing for conversations with specialists, highlighting potential treatment options and navigating cost and coverage

JERSEY CITY, N.J., October 15, 2021--(BUSINESS WIRE)--Organon (NYSE: OGN) today announced the launch of a new website – Fertility Journey – that helps inform and empower people with resources and information needed to navigate the process of fertility care. The website aims to meet people wherever they are on their fertility journey and equip them with knowledge and questions for consideration to feel prepared and empowered throughout their journey.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211015005054/en/

(Photo: Business Wire)

"Infertility is a significant public health issue in the U.S. While the issue affects both men and women, the burden of treatment typically falls on women, with 7.3 million women reporting the use of infertility services in the U.S. from 2006-2010," said Dr. Barbara Stegmann, clinical lead of women’s health for Organon. "We want to provide support to anyone looking to start a family and for those accompanying them. I am proud to work at Organon where we are truly devoted to understanding the journey."

Every fertility journey is a personal one, but many on this road have similar questions. When visiting Organon’s Fertility Journey website you can access resources and information which include:

  • Insights to understand what can cause infertility and the many factors that can contribute to it in both men and women

  • What to expect from the first fertility consultation, how to best prepare for that appointment – including questions for consideration

  • A description of clinical tests or evaluations that may be conducted to help identify an individualized fertility treatment plan and ways to navigate the associated cost and coverage options

  • Help prepare for the emotional and physical challenges that may arise

"At Organon, we are fully invested in listening to her needs and are dedicated to championing care by creating options built around these needs," said Mike Pohleven, U.S. Fertility Lead at Organon. "This launch marks a key milestone in our mission to elevate fertility education and provide resources to help people along their fertility journey, and reiterates our commitment to being a source of information for women and their care team."

The website launch is in tandem with the 77th American Society for Reproductive Medicine (ASRM) Scientific Congress and Expo in Baltimore, MD (October 17-20) where Organon will be participating in fertility conversations and discussing their current fertility products.

About Organon

Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health, including business development like recently acquired Alydia Health, a medical device company focused on postpartum hemorrhage. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging Organon’s scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with its headquarters located in Jersey City, New Jersey.

Forward-Looking Statement of Organon

This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management’s expectations about Organon’s future prospects. Forward-looking statements may be identified by words such as "aims," "potential," "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "will" or words of similar meaning. These statements are based upon the current beliefs and expectations of Organon’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, difficulties developing and sustaining relationships with commercial counterparties, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the ongoing COVID-19 pandemic and emergence of variant strains; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Organon’s ability to accurately predict its future financial results and performance; Organon’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Organon’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Organon does not undertake any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Organon’s filings with the Securities and Exchange Commission ("SEC"), including its registration statement on Form 10, available at the SEC’s Internet site (www.sec.gov).

View source version on businesswire.com: https://www.businesswire.com/news/home/20211015005054/en/

Contacts

Media:

Karissa Peer
(614) 314-8094

Kim Hamilton
(908) 391-0131

Investors:

Jennifer Halchak
(201) 275-2711

Edward Barger
(267) 614-4669

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting